![David J. Lockhart](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David J. Lockhart
Amministratore Delegato presso Transcriptx, Inc.
Posizioni attive di David J. Lockhart
Società | Posizione | Inizio | Fine |
---|---|---|---|
ReCode Therapeutics, Inc.
![]() ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Direttore/Membro del Consiglio | - | - |
Direttore Tecnico/Scientifico/R&S | 11/01/2022 | - | |
Presidente | - | - | |
Amministratore Delegato | - | 11/01/2022 | |
Transcriptx, Inc.
![]() Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Amministratore Delegato | 01/12/2014 | - |
Storia della carriera di David J. Lockhart
Precedenti posizioni note di David J. Lockhart
Società | Posizione | Inizio | Fine |
---|---|---|---|
AMICUS THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/01/2006 | 31/12/2013 |
AMBIT BIOSCIENCES CORP | Direttore Tecnico/Scientifico/R&S | 01/07/2005 | 01/07/2005 |
Fondatore | 01/07/2005 | 01/07/2005 | |
Presidente | - | 01/07/2005 | |
Novartis Institute for Functional Genomics, Inc.
![]() Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/02/1999 | 01/07/2000 |
AFFYMETRIX, INC. | Corporate Officer/Principal | - | - |
Formazione di David J. Lockhart
Stanford University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Chief Tech/Sci/R&D Officer | 3 |
Corporate Officer/Principal | 2 |
President | 2 |
Settori
Health Technology | 6 |
Consumer Services | 2 |
Commercial Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
AMICUS THERAPEUTICS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Affymetrix, Inc.
![]() Affymetrix, Inc. Medical SpecialtiesHealth Technology Affymetrix, Inc. develops, manufactures and sells products and services for genetic analysis. The company was founded by Stephen P. A. Fodor in 1992 and is headquartered in Santa Clara, CA. | Health Technology |
Ambit Biosciences Corp.
![]() Ambit Biosciences Corp. Pharmaceuticals: MajorHealth Technology Ambit Biosciences Corp. develops pharmaceutical drugs. It engages in discovery, development and commercialization of small-molecule kinase inhibitors for the treatment of cancer. The firm provides drug to treat unmet medical needs in oncology, autoimmune and inflammatory diseases. The company was founded on May 17, 2000 and is headquartered in San Diego, CA. | Health Technology |
Novartis Institute for Functional Genomics, Inc.
![]() Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Commercial Services |
ReCode Therapeutics, Inc.
![]() ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology ReCode Therapeutics, Inc. operates as a biopharmaceutical company. It develops precision medicines for pulmonary diseases. The company is headquartered in Irvin, TX. | Health Technology |
Transcriptx, Inc.
![]() Transcriptx, Inc. BiotechnologyHealth Technology Part of ReCode Therapeutics, Inc., Transcriptx, Inc. develops mRNA therapies intended to treat primary ciliary dyskinesia. The company is based in Menlo Park, CA. David J. Lockhart has been the CEO of the company since 2014. Transcriptx was acquired by ReCode Therapeutics, Inc. on March 26, 2020. | Health Technology |
- Borsa valori
- Insiders
- David J. Lockhart
- Esperienza